Park Ha Biological Technology (BYAH) Registration Filing summary

Management team and governance

• CEO is Xiaoqiu Zhang, with Xiaoyan Zhu as CFO and Xinyu Li as CTO; all have signed the registration statement.

• Board includes directors Li Wang, Yanan Shan, Qixiong Sheng, and Xiaozhong Yu.

• U.S. authorized representative is Cogency Global Inc., signed by Colleen A. De Vries.

• Employment agreements for CEO, CFO, and CTO are referenced as exhibits.

• Code of Business Conduct and Ethics, Insider Trading Policies, and Executive Compensation Recovery Policy are included as referenced exhibits.

Offering details and pricing

• IPO completed in December 2024 with 1,200,000 Ordinary Shares at $4.00 per share, raising $4.8 million gross.

• Over-allotment option partially exercised in January 2025 for 174,403 shares, raising $697,612 gross.

• Shares began trading on Nasdaq under the symbol "PHH" on December 27, 2024.

Financial performance and metrics

• As of the date of the prospectus, 33,874,403 Ordinary Shares are issued and outstanding.

• 3,000,000 shares issued under the 2025 Share Incentive Plan in March 2025; 4,500,000 more under the amended plan in July 2025.